Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
Crossref DOI link: https://doi.org/10.1007/s00392-017-1098-x
Published Online: 2017-03-14
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hohnloser, Stefan H.
Basic, Edin
Nabauer, Michael
Funding for this research was provided by:
BMS/Pfizer
License valid from 2017-03-14